GGrantIndex
← Leaderboards

Deborah T Hung

Massachusetts General Hospital

$41,850,756
Attributed
$41,850,756
Total exposure
19
Grants
19
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $14.7M · FY200523
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$75,730,113 · 20

By mechanism

U19$55,263,637 · 7
R01$14,188,038 · 3
R33$2,893,646 · 2
R21$2,870,008 · 6
K08$490,320 · 1
R03$24,464 · 1

Top collaborators

No co-investigators on record.

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Antibiotics

Research focus

AntibioticsResistanceInfectionPathogenSmall MoleculeResponseIn VivoCellsBasePharmaceutical PreparationsComplexProteinsPseudomonas AeruginosaIn VitroBiologicalPathway InteractionsBacteriaLeadTechnologyAntimicrobialGenomicsAnimal ModelNovel TherapeuticsAntibiotic Resistance

Grant awards (58)

Innovative technologies to transform antibiotic discovery.$6,495,548
U19 · FY2023 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 1 Genomic applications to transform Gram-negative Antibiotic discovery$2,214,724
U19 · FY2023 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugates$1,257,364
U19 · FY2023 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Administrative Core$328,904
U19 · FY2023 · AI · contact PI
Innovative technologies to transform antibiotic discovery.$6,621,136
U19 · FY2022 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 1 Genomic applications to transform Gram-negative Antibiotic discovery$1,852,108
U19 · FY2022 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugates$1,193,998
U19 · FY2022 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Administrative Core$390,879
U19 · FY2022 · AI · contact PI
Innovative technologies to transform antibiotic discovery.$6,735,434
U19 · FY2021 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 1 Genomic applications to transform Gram-negative Antibiotic discovery$1,870,233
U19 · FY2021 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugates$1,453,105
U19 · FY2021 · AI · contact PI
New targets against tuberculosis$1,076,804
R01 · FY2021 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Administrative Core$354,372
U19 · FY2021 · AI · contact PI
Innovative technologies to transform antibiotic discovery.$6,944,328
U19 · FY2020 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Administrative Core$3,052,404
U19 · FY2020 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 1 Genomic applications to transform Gram-negative Antibiotic discovery$2,212,100
U19 · FY2020 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugates$1,378,141
U19 · FY2020 · AI · contact PI
New targets against tuberculosis$1,080,104
R01 · FY2020 · AI · contact PI
Innovative technologies to transform antibiotic discovery.$7,082,911
U19 · FY2019 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 1 Genomic applications to transform Gram-negative Antibiotic discovery$2,140,171
U19 · FY2019 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugates$1,312,178
U19 · FY2019 · AI · contact PI
RNA based diagnostics for rapid pathogen identification and drug resistance$1,191,782
R01 · FY2019 · AI · contact PI
New targets against tuberculosis$1,083,404
R01 · FY2019 · AI · contact PI
Innovative technologies to transform antibiotic discovery. Administrative Core$373,599
U19 · FY2019 · AI · contact PI
RNA based diagnostics for rapid pathogen identification and drug resistance$109,091
R01 · FY2019 · AI · contact PI
RNA based diagnostics for rapid pathogen identification and drug resistance$1,215,572
R01 · FY2018 · AI · contact PI
New targets against tuberculosis$1,156,431
R01 · FY2018 · AI · contact PI
New targets against tuberculosis$1,505,690
R01 · FY2017 · AI · contact PI
RNA based diagnostics for rapid pathogen identification and drug resistance$1,239,362
R01 · FY2017 · AI · contact PI
A "radical" approach to tuberculosis infection$549,000
R33 · FY2017 · AI · contact PI
RNA based diagnostics for rapid pathogen identification and drug resistance$1,229,835
R01 · FY2016 · AI · contact PI
A "radical" approach to tuberculosis infection$531,000
R33 · FY2016 · AI · contact PI
Multiplexed targeting of Pseudomonas aeruginosa essential outer membrane proteins$452,898
R33 · FY2016 · AI · contact PI
Exploiting bacterial uptake as a universal platform for antibacterial development$245,198
R21 · FY2016 · AI · contact PI
Chemical biological studies of pyroptotic cell death$217,500
R21 · FY2016 · AI · contact PI
RNA based diagnostics for rapid pathogen identification and drug resistance$1,552,625
R01 · FY2015 · AI · contact PI
A "radical" approach to tuberculosis infection$531,000
R33 · FY2015 · AI · contact PI
Multiplexed targeting of Pseudomonas aeruginosa essential outer membrane proteins$402,293
R33 · FY2015 · AI · contact PI
Chemical biological studies of pyroptotic cell death$261,000
R21 · FY2015 · AI · contact PI
Exploiting bacterial uptake as a universal platform for antibacterial development$241,235
R21 · FY2015 · AI · contact PI
Development of a small molecule probe targeting non-replicating M. tuberculosis$221,250
R21 · FY2015 · AI · contact PI
Multiplexed targeting of Pseudomonas aeruginosa essential outer membrane proteins$427,455
R33 · FY2014 · AI · contact PI
Development of a small molecule probe targeting non-replicating M. tuberculosis$265,500
R21 · FY2014 · AI · contact PI
A "radical" approach to tuberculosis infection$229,839
R21 · FY2014 · AI · contact PI
A "radical" approach to tuberculosis infection$233,550
R21 · FY2013 · AI · contact PI
Multiplexed targeting of Pseudomonas aeruginosa essential outer membrane proteins$233,141
R21 · FY2013 · AI · contact PI
Elucidating Pseudomonas aeruginosa non-canonical two component system signaling$217,500
R21 · FY2013 · AI · contact PI
Chemical Biological and Genomic Approaches to Bacterial Virulence Regulation$433,694
R01 · FY2012 · AI · contact PI
Elucidating Pseudomonas aeruginosa non-canonical two component system signaling$261,875
R21 · FY2012 · AI · contact PI
Multiplexed targeting of Pseudomonas aeruginosa essential outer membrane proteins$242,420
R21 · FY2012 · AI · contact PI
Chemical Biological and Genomic Approaches to Bacterial Virulence Regulation$433,694
R01 · FY2011 · AI · contact PI
Chemical Biological and Genomic Approaches to Bacterial Virulence Regulation$438,075
R01 · FY2010 · AI · contact PI
Chemical Biological and Genomic Approaches to Bacterial Virulence Regulation$441,875
R01 · FY2009 · AI · contact PI
Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tubercu$24,464
R03 · FY2009 · MH · contact PI
Chemical genetic approach to Vibrio cholerae pathogensis$125,280
K08 · FY2007 · AI · contact PI
Chemical genetic approach to Vibrio cholerae pathogensis$125,280
K08 · FY2006 · AI · contact PI
Chemical genetic approach to Vibrio cholerae pathogensis$125,280
K08 · FY2005 · AI
Chemical genetic approach to Vibrio cholerae pathogensis$114,480
K08 · FY2004 · AI